You just read:

BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies

News provided by

BioMarin Pharmaceutical Inc.

Aug 02, 2017, 16:01 ET